You need JavaScript to view this

Basal ganglia disorders studied by positron emission tomography

Journal Article:

Abstract

Recent development of positron emitting radioligands has made it possible to investigate the alterations of neurotransmitter systems associated with basal ganglia disorders in vivo. The functional integrity of nigro-striatal dopaminergic terminals may be studied with [[sup 18]F]6-fluoro-L-dopa ([[sup 18]F]dopa), and striatal dopamine receptor density with suitable PET ligands. [[sup 18]F]dopa uptake in the striatum (putamen) is markedly reduced in patients with Parkinson's disease (PD). [[sup 18]F]dopa-PET is capable of detecting sub-clinical nigral dysfunction in asymptomatic patients with familial PD and those who become Parkinsonian on conventional doses of dopamine receptor antagonists. While putamen [[sup 18]F]dopa uptake is reduced to a similar level in patients with multiple system atrophy (MSA) and PD, caudate [[sup 18]F] dopa uptake is lower in MSA than PD. However, [[sup 18]F]dopa PET cannot consistently distinguish MSA from PD because individual ranges of caudate [[sup 18]F]dopa uptake overlap. D[sub 1] and D[sub 2] receptor binding is markedly reduced in the striatum (posterior putamen) of MSA patients. Therefore, dopamine receptor imaging is useful for the differential diagnosis of MSA and PD. Similar marked reductions in putamen and caudate [[sup 18]F]dopa uptake have been observed in patients with progressive supranuclear palsy (PSP). Moderate reductions in D[sub 2] receptor binding  More>>
Authors:
Shinotoh, Hitoshi [1] 
  1. Chiba Univ. (Japan). School of Medicine
Publication Date:
Apr 01, 1994
Product Type:
Journal Article
Reference Number:
JPN-94-008320; EDB-94-155150
Resource Relation:
Journal Name: Shinkei Kenkyu No Shinpo (Advances in Neurological Sciences); (Japan); Journal Volume: 38:2
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CEREBRUM; POSITRON COMPUTED TOMOGRAPHY; AGE DEPENDENCE; ATROPHY; CARBON 11; DOPAMINE; ELDERLY PEOPLE; FLUORINE 18; GANGLIONS; MENTAL DISORDERS; NERVE CELLS; REVIEWS; UPTAKE; ADULTS; AGE GROUPS; AGED ADULTS; AMINES; ANIMAL CELLS; AROMATICS; AUTONOMIC NERVOUS SYSTEM AGENTS; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; BRAIN; CARBON ISOTOPES; CARDIOTONICS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DOCUMENT TYPES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; EVEN-ODD NUCLEI; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; HUMAN POPULATIONS; HYDROXY COMPOUNDS; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LIGHT NUCLEI; MINORITY GROUPS; MINUTES LIVING RADIOISOTOPES; NANOSEC LIVING RADIOISOTOPES; NERVOUS SYSTEM; NEUROREGULATORS; NUCLEI; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; ORGANS; PATHOLOGICAL CHANGES; PHENOLS; POLYPHENOLS; POPULATIONS; RADIOISOTOPES; SOMATIC CELLS; SYMPATHOMIMETICS; TOMOGRAPHY; 550601* - Medicine- Unsealed Radionuclides in Diagnostics
OSTI ID:
6925966
Country of Origin:
Japan
Language:
Japanese
Other Identifying Numbers:
Journal ID: ISSN 0001-8724; CODEN: SKNSAF
Submitting Site:
JPN
Size:
Pages: 276-285
Announcement Date:
Nov 15, 1994

Journal Article:

Citation Formats

Shinotoh, Hitoshi. Basal ganglia disorders studied by positron emission tomography. Japan: N. p., 1994. Web.
Shinotoh, Hitoshi. Basal ganglia disorders studied by positron emission tomography. Japan.
Shinotoh, Hitoshi. 1994. "Basal ganglia disorders studied by positron emission tomography." Japan.
@misc{etde_6925966,
title = {Basal ganglia disorders studied by positron emission tomography}
author = {Shinotoh, Hitoshi}
abstractNote = {Recent development of positron emitting radioligands has made it possible to investigate the alterations of neurotransmitter systems associated with basal ganglia disorders in vivo. The functional integrity of nigro-striatal dopaminergic terminals may be studied with [[sup 18]F]6-fluoro-L-dopa ([[sup 18]F]dopa), and striatal dopamine receptor density with suitable PET ligands. [[sup 18]F]dopa uptake in the striatum (putamen) is markedly reduced in patients with Parkinson's disease (PD). [[sup 18]F]dopa-PET is capable of detecting sub-clinical nigral dysfunction in asymptomatic patients with familial PD and those who become Parkinsonian on conventional doses of dopamine receptor antagonists. While putamen [[sup 18]F]dopa uptake is reduced to a similar level in patients with multiple system atrophy (MSA) and PD, caudate [[sup 18]F] dopa uptake is lower in MSA than PD. However, [[sup 18]F]dopa PET cannot consistently distinguish MSA from PD because individual ranges of caudate [[sup 18]F]dopa uptake overlap. D[sub 1] and D[sub 2] receptor binding is markedly reduced in the striatum (posterior putamen) of MSA patients. Therefore, dopamine receptor imaging is useful for the differential diagnosis of MSA and PD. Similar marked reductions in putamen and caudate [[sup 18]F]dopa uptake have been observed in patients with progressive supranuclear palsy (PSP). Moderate reductions in D[sub 2] receptor binding have been reported in the striatum of PSP patients. The reduction in D[sub 2] receptor binding is more prominent in the caudate than putamen. Striatal [[sup 18]F]dopa uptake is normal or only mildly reduced in patients with dopa responsive dystonia (DRD). D[sub 2] receptor binding is markedly reduced in patients with Huntington's disease, while striatal [[sup 18]F]dopa uptake is normal or mildly reduced. In summary, PET can demonstrate characteristic patterns of disruption of dopaminergic systems associated with basal ganglia disorders. (J.P.N.) 55 refs.}
journal = {Shinkei Kenkyu No Shinpo (Advances in Neurological Sciences); (Japan)}
volume = {38:2}
journal type = {AC}
place = {Japan}
year = {1994}
month = {Apr}
}